Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4


Dicerna Pharn Form 4	naceuticals Inc									
June 16, 2016									PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						N OMB	3235-0287			
Check this			Wa	shington	, D.C. 20	549		Number: Expires:	January 31,	
Subject to Section 16. Form 4 or			F CHANGES IN BENEFICIAL OWNERSHIP SECURITIES					Estimated burden hou response	urs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Re	esponses)									
1. Name and Address of Reporting Person <u>*</u> Halak Brian K			2. Issuer Name and Ticker or Trading Symbol Dicerna Pharmaceuticals Inc				5. Relationship of Reporting Person(s) to Issuer			
				[DRNA]			(Check all applicable)			
(Last) (First) (Middle) C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE			3. Date of Earliest Transaction (Month/Day/Year) 06/14/2016				X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street) PRINCETON, NJ 08542			4. If Amendment, Date Original Filed(Month/Day/Year)			1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned	
	. Transaction Date Month/Day/Year)	Execution any	Date, if		4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price				
Reminder: Repor	rt on a separate line	e for each c	lass of sec	urities bene	-		-	otion of	SEC 1474	
			Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.							
	Tab					posed of, or convertible s	Beneficially Owner securities)	d		
1. Title of 2.	3. Trans	action Date	e 3A. Dec	emed	4.	5. Number	of 6. Date Exerci	sable and	7. Title and Amount of	

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Underlying Securities

Expiration Date

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4



Reporting Owners

Reporting Owner Name / Address								
	Director	10% Owner	Officer	Other				
Halak Brian K C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJ 08542	Х							
Signatures								
/s/ Lisa A. Kraeutler, Attorney-in-Fact	06/	15/2016						
**Signature of Reporting Person		Date						
Explanation of Responses:								

u nespunses.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.